Xenon Pharmaceuticals (XENE) Other Operating Expenses (2014 - 2026)

Xenon Pharmaceuticals (XENE) has 7 years of Other Operating Expenses data on file, last reported at -$123.2 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at -$123.2 million, down 2128.31% year-over-year; the trailing twelve-month figure through Mar 2026 was -$525.4 million (down 199.6% YoY), and the FY2025 annual result was -$407.7 million, down 34.56% from the prior year.
• Other Operating Expenses improved to -$123.2 million in Q1 2026 per XENE's latest filing, from -$389.4 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at -$5.5 million in Q1 2025 and troughed at -$389.4 million in Q4 2025.
• A 5-year average of -$101.5 million and a median of -$78.8 million in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Operating Expenses surged 91.48% in 2025, then sank 2128.31% in 2026.
• A 5-year view of Other Operating Expenses shows it stood at -$133.6 million in 2022, then plunged by 63.2% to -$218.1 million in 2023, then jumped by 60.85% to -$85.4 million in 2024, then plunged by 356.07% to -$389.4 million in 2025, then jumped by 68.35% to -$123.2 million in 2026.
• Business Quant data shows XENE's Other Operating Expenses at -$123.2 million in Q1 2026, -$389.4 million in Q4 2025, and -$6.7 million in Q3 2025.